Work

Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

Year: 2023

Type: other

Abstract: Supplementary Figure S6. Measurements of tumor growth after treatment with veliparib, TMZ or their combination in TMZ-sensitive versus resistant GBM models in vivo.

DOI: 10.1158/1078-0432.22455254.v1

Authors: Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson, Felix Boakye-Agyeman, Katrina K. Bakken, Sani H. Kizilbash, Mark A. Schroeder, Joel Reid, Jann N. Sarkaria

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361910468

Cites:

Cited by:

Related to: 10